Aurobindo Pharma is currently trading at Rs. 770.10, up by 12.50 points or 1.65% from its previous closing of Rs. 757.60 on the BSE.
The scrip opened at Rs. 758.70 and has touched a high and low of Rs. 771.75 and Rs. 753.15 respectively. So far 65596 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 844.00 on 19-Oct-2016 and a 52 week low of Rs. 504.00 on 29-May-2017.
Last one week high and low of the scrip stood at Rs. 771.75 and Rs. 727.10 respectively. The current market cap of the company is Rs. 45080.72 crore.
The promoters holding in the company stood at 51.87%, while institutions and non-institutions held 34.15% and 13.98% respectively.
Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg. Esomeprazole Magnesium Delayed-Release Capsules OTC, a therapeutic equivalent generic version of AstraZeneca’s Nexium 24HR Capsules. The product will be launched immediately.
Nexium 24HR (Esomeprazole Magnesium) capsules are indicated to treat frequent heartburn (occurs 2 or more days a week). The approved product has an approximate annual sale in excess of $300 million.
This is the 127th ANDA (including 23 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. The company now has a total of 335 ANDA approvals (296 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1508.40 |
Dr. Reddys Lab | 6259.80 |
Cipla | 1410.60 |
Zydus Lifesciences | 952.40 |
Lupin | 1618.90 |
View more.. |